Biotech Jobs Could Elude Postdocs As Firms Seek Experienced Workers

Postdocs fresh from academia looking to biotechnology this spring are in for a big letdown. While postdocs once were the bread and butter of a fledgling industry, the years of their being snapped up out of school have given way to their becoming an afterthought as the field shifts its focus from innovation to commercialization of existing products under development. The recruitment focus of these companies now centers on experienced bachelor's and master's degree holders and specialized Ph.D.'s

Written byRobin Eisner
| 7 min read

Register for free to listen to this article
Listen with Speechify
0:00
7:00
Share

So say leaders of prominent biotech companies, their personnel directors, head hunters, and industry analysts of an employment phenomenon that is the result of the companies' emphasis on bringing the products such Ph.D.'s once discovered to market.

"The largest growth area for biotechnology companies in 1991 and in the next few years will be manufacturing and commercialization," says David Jensen, of Search Masters International, an executive and scientific search firm in Sedona, Ariz. The bulk of these positions will be filled with non-Ph.D. technicians and engineers who have a few years' industry experience, he says.

Other human resources specialists agree, adding that there is always a demand at biotech firms for highly skilled doctorate-level specialists, such as microbial physiologists.

"Good people are still hard to find. Often the areas we're looking into are cutting-edge, and not too many people are out there," says Chris Giffin, senior recruiter at the Thousand ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies